Loading…
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-128M | $-125M | $-105M | -38.3% | - | -23.0% |
| 2024 | $0M | $-153M | $-162M | $-132M | -38.2% | - | 29.3% |
| 2023 | $0M | $-138M | $-125M | $-123M | -39.5% | - | -48.5% |
| 2022 | $0M | $-143M | $-243M | $-120M | -59.0% | - | - |
| 2021 | - | - | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0 | 0 | 0 | 0 |
| Operating Revenue | - | 0 | 0 | 0 | 0 |
| Operating Expense | - | 145.45 | 141.52 | 157.09 | 131.40 |
| Research And Development | - | 112.46 | 103.82 | 115.36 | 92.85 |
| Selling General And Administration | - | 32.99 | 37.70 | 41.73 | 38.55 |
| Total Expenses | - | 145.45 | 141.52 | 157.09 | 131.40 |
| Operating Income | - | -145.45 | -141.52 | -157.09 | -131.40 |
| Total Operating Income As Reported | - | -247.45 | -141.52 | -179.59 | -140.90 |
| EBITDA | - | -142.81 | -137.79 | -153.28 | -128.30 |
| Normalized EBITDA | - | -40.81 | -137.79 | -130.78 | -118.80 |
| EBIT | - | -145.45 | -141.52 | -157.09 | -131.40 |
| Interest Income | - | 4.90 | 16.71 | 20.09 | 16.61 |
| Net Interest Income | - | 4.90 | 16.71 | 20.09 | 16.61 |
| Other Non Operating Income Expenses | - | -0.26 | -0.23 | -2.16 | -0.25 |
| Other Income Expense | - | -102.26 | -0.23 | -24.66 | -9.75 |
| Interest Income Non Operating | - | 4.90 | 16.71 | 20.09 | 16.61 |
| Net Non Operating Interest Income Expense | - | 4.90 | 16.71 | 20.09 | 16.61 |
| Pretax Income | - | -242.80 | -125.04 | -161.65 | -124.55 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -242.80 | -125.04 | -161.65 | -124.55 |
| Net Income From Continuing And Discontinued Operation | - | -242.80 | -125.04 | -161.65 | -124.55 |
| Net Income From Continuing Operation Net Minority Interest | - | -242.80 | -125.04 | -161.65 | -124.55 |
| Net Income | - | -242.80 | -125.04 | -161.65 | -124.55 |
| Net Income Common Stockholders | - | -242.80 | -125.04 | -161.65 | -124.55 |
| Net Income Including Noncontrolling Interests | - | -242.80 | -125.04 | -161.65 | -124.55 |
| Normalized Income | - | -140.80 | -125.04 | -139.15 | -115.05 |
| Diluted NI Availto Com Stockholders | - | -242.80 | -125.04 | -161.65 | -124.55 |
| Basic Average Shares | - | 122.02 | 150.18 | 233.82 | 283.53 |
| Diluted Average Shares | - | 122.02 | 150.18 | 233.82 | 283.53 |
| Reconciled Depreciation | - | 2.64 | 3.73 | 3.80 | 3.11 |
| Total Unusual Items | - | -102 | 0 | -22.50 | -9.50 |
| Total Unusual Items Excluding Goodwill | - | -102 | 0 | -22.50 | -9.50 |
| Special Income Charges | - | -102 | 0 | -22.50 | -9.50 |
| Other Special Charges | 28.34 | 102 | - | 22.50 | 9.50 |
| General And Administrative Expense | - | 32.99 | 37.70 | 41.73 | 38.55 |
| Other Gand A | - | 32.99 | 37.70 | 41.73 | 38.55 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Erasca, Inc.this co. | ERAS | $4.1B | -33.13 | 12.69 | -38.3% | -31.96 |
| Dianthus Therapeutics, Inc. | DNTH | $4.6B | -28.33 | 9.32 | -32.9% | -25.63 |
| Amicus Therapeutics, Inc. | FOLD | $4.5B | -167.83 | 16.59 | -9.9% | 88.80 |
| Celcuity Inc. | CELC | $4.5B | -25.47 | 44.85 | -176.1% | -29.21 |
| Travere Therapeutics, Inc. | TVTX | $4.3B | -168.11 |
| - |
| - |
| 37.40 |
| -22.2% |
| 203.89 |
| 10x Genomics, Inc. | TXG | $4.3B | -97.67 | 5.34 | -5.5% | 988.34 |
| LivaNova PLC | LIVN | $4.0B | -16.70 | 3.37 | -20.2% | -34.40 |
| Edgewise Therapeutics, Inc. | EWTX | $4.0B | -23.87 | 7.67 | -32.1% | -20.88 |
| Oruka Therapeutics, Inc. | ORKA | $3.8B | - | 9.90 | -22.5% | - |
| Peer Median | - | -28.33 | 9.61 | -22.4% | -20.88 | |